Purified anti-human CD272 (BTLA)

B and T lymphocyte attenuator (BTLA) is an Ig superfamily coinhibitory receptor with structural similarity to programmed cell death 1 (PD-1) and CTLA-4. BTLA is expressed on B cells, T cells, macrophages, dendritic cells, NKT cells, and NK cells. Engagement of BTLA by its ligand Herpes Virus Entry Mediator (HVEM) is critical for negatively regulating immune response. The absence of BTLA with HVEM inhibitory interactions leads to increased experimental autoimmune encephalomyelitis severity, enhanced rejection of partially mismatched allografts, an increased CD8+ memory T cell population, increased severity of colitis, and reduced effectiveness of T regulatory cells. BTLA plays an important role in the induction of peripheral tolerance of both CD4+ and CD8+ T cells in vivo. Tolerant T cells have significant up-regulated expression of BTLA compared with effector and naïve T cells. BTLA may cooperate with CTLA-4 and PD-1 to control T cell tolerance and autoimmunity. It has been reported that BTLA may regulate T cell function through binding to B7-H4.

Prices direct from BioLegend

Quick response times

Exclusive Absave savings/discounts

SPECIFICATIONS

Catalog Number

344502

Size

100 microg

Applications

FC

Hosts

Mouse

Reactivities

Hum

Clone

MIH26

Antigen

Human BTLA transfected cells

Gene Id

151888

Isotype

Mouse IgG2a, kappa

Clonality

Monoclonal

Dilutions

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining, the suggested use of this reagent is ?2.0 microg per million cells in 100 microl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Storage Temp

4 C

Concentration

0.5 mg/ml

Shipping Temp

Ambient RT

Storage Buffer

The antibody solution should be stored undiluted at 4C.

Alternative Names

BTLA, B and T lymphocyte attenuator

Regulatory Status

RUO